Health · Pharma & Biotech · 2 hrs ago
Oral deucrictibant reduced hereditary angioedema attacks in a phase III trial
A pivotal phase III trial found that oral deucrictibant substantially reduced HAE attacks when used to prevent them.
HAE is short for hereditary angioedema.
Deucrictibant is a bradykinin B2 receptor antagonist, and the trial tested an extended-release version.
The study was described as a pivotal trial, a major step in evaluating a medicine.
Its results put the new oral option alongside injectable treatments for prevention.
The available information does not say what happens next.
Oral deucrictibant substantially reduced hereditary angioedema attacks in a pivotal phase III trial.
The drug was used prophylactically.
Deucrictibant is a bradykinin B2 receptor antagonist.
The trial assessed an extended-release form of deucrictibant for its primary endpoint.
- Who
- People with hereditary angioedema.
- What
- A phase III trial found that prophylactic oral deucrictibant substantially reduced attacks.
- When
- Not stated.
- Where
- Not stated.
- Why
- Deucrictibant was used as prophylaxis to reduce hereditary angioedema attacks.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Deucrictibant
- Drug class
- Bradykinin B2 receptor antagonist
- Trial phase
- Phase III
- Use
- Prophylactic
- Form assessed
- Extended-release formulation